BTIG reiterates Buy on BillionToOne stock, keeps $130 target
BTIG maintained its Buy rating and $130 target on BillionToOne (BLLN) after Q3 earnings. Revenue grew 47% YoY, with oncology up 96%. 2026 guidance raised to $460M-$470M. Stock down 12% post-earnings but up 42.5% in 6 months. P/E ratio at 137.73. NorthStar Clear test launch planned.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a fresh catalyst that could attract buying interest, especially given the company’s expanding oncology business.
Market read
Earnings beat and guidance lift are material for traders; the stock may see upside pressure.
What to watch
Potential volatility from regulatory scrutiny of blood‑based MRD tests.
Background
BTIG’s coverage of BillionToOne follows the company’s Q3 2026 earnings release, highlighting revenue growth and guidance lift.
Ticker impact
BTIG reiterated a Buy rating and raised the 2026 revenue guidance for BillionToOne after its Q3 earnings beat and strong guidance.
likely upward pressure as the market prices in the higher revenue guidance and earnings beat.
The company posted 47% YoY revenue growth, beat EPS estimates, and lifted its full‑year revenue range, all fresh data that can drive buying.
Market effects
Strong oncology growth may lift peer biotech and cancer‑diagnostics stocks.
Positive for US biotech sector, modest impact on broader market.
Limited to investors tracking US biotech earnings.
Counterpoint
The high P/E of 137 may indicate overvaluation despite growth.
Key entities
- companyBillionToOne Inc
Biotech firm reporting Q3 2026 earnings and guidance.
- analystBTIG
Equity research firm reiterating a Buy rating.
